|
Video: What is a Stock Split?
|
|
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. Co.'s primary advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3 in clinical development for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. Co. is also developing CFT8634, an orally bioavailable Bifunctional Degradation Activating Compounds degrader of a protein target called BRD9, for synovial sarcoma and SMARCB1-deleted solid tumors. According to our C4 Therapeutics stock split history records, C4 Therapeutics has had 1 split. | |
|
C4 Therapeutics (CCCC) has 1 split in our C4 Therapeutics stock split history database. The split for CCCC took place on November 23, 2001. This was a 1 for 2 reverse split, meaning for each 2 shares of CCCC owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 500 share position following the split.
When a company such as C4 Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the C4 Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 500 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into C4 Therapeutics shares, starting with a $10,000 purchase of CCCC, presented on a split-history-adjusted basis factoring in the complete C4 Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/05/2020 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$26.57 |
|
End price/share: |
$6.47 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-75.65% |
|
Average Annual Total Return: |
-32.80% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$2,435.40 |
|
Years: |
3.55 |
|
|
|
Date |
Ratio |
11/23/2001 | 1 for 2 |
|
|